More Company News

Scancell

Vaccitech technology licenced to advance Modi-2
07 Nov 2022Read More

Scancell

First patient dosed in expansion phase of ModiFY
31 Oct 2022Read More

Scancell

FY22 results for year ended 30 April 2022
28 Oct 2022Read More

Scancell

Directorate changes
26 Oct 2022Read More

Scancell

Commercial licence agreement with Genmab
25 Oct 2022Read More

Scancell

Change of NOMAD
13 Oct 2022Read More

Scancell

Preclinical data at EuroMAbNet
23 Sep 2022Read More

Scancell

First patient dosed in Cohort 2 of the ModiFY Phase I clinical trial
16 Aug 2022Read More

Scancell

Scancell to produce TCB antibodies
23 Jun 2022Read More

Scancell

Phase 2 SCIB1 trial expanded
15 Jun 2022Read More

1 2 3 4 … 8
Return to Scancell
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).